US Bancorp DE Trims Stock Position in Elevance Health, Inc. $ELV

US Bancorp DE lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 11.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,363 shares of the company’s stock after selling 6,624 shares during the period. US Bancorp DE’s holdings in Elevance Health were worth $18,005,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in ELV. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in shares of Elevance Health in the fourth quarter worth approximately $5,941,000. Evergreen Wealth Management LLC boosted its stake in shares of Elevance Health by 33.5% in the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after acquiring an additional 4,336 shares during the last quarter. Blume Capital Management Inc. boosted its stake in shares of Elevance Health by 236.7% in the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after acquiring an additional 4,320 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Elevance Health by 31.1% in the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after acquiring an additional 109,462 shares during the last quarter. Finally, Synergy Asset Management LLC lifted its position in Elevance Health by 100.0% during the third quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock worth $33,712,000 after buying an additional 52,167 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

NYSE:ELV opened at $372.78 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $424.24. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $80.95 billion, a P/E ratio of 15.86, a P/E/G ratio of 2.14 and a beta of 0.49. The stock’s fifty day moving average is $310.69 and its two-hundred day moving average is $331.90.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research report on Tuesday. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Bank of America upgraded Elevance Health from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $405.00 to $435.00 in a research report on Wednesday. Evercore lifted their price objective on Elevance Health from $345.00 to $360.00 in a research report on Thursday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Elevance Health from $332.00 to $363.00 and gave the stock a “hold” rating in a research report on Thursday, April 23rd. Thirteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.